Mineralys Q3 net loss $22.8M; cash $265.9M; Phase 3 Launch-HTN start on track for 2H2023, topline delayed to 2H2025

Mineralys Therapeutics, Inc.

2023-Q3 EPS reported -$1.36

Net loss $22.8M (Q3 2023) vs $6.7M (Q3 2022); R&D expenses $22.5M, up from $6.1M.
Cash, cash equivalents and investments $265.9M as of Sep 30, 2023; expected to fund operations through mid-2025.
Advance-HTN topline data revised from 1H2024 to 2H2024 due to protocol amendment and enrollment curve.
Phase 3 Launch-HTN trial remains on track to initiate in 2H2023; topline data now expected in 2H2025.
Explore-CKD Phase 2 trial expected to start in 2H2023 with topline data in Q4 2024–Q1 2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

Mineralys Therapeutics, Inc. reported financial results for the quarter ended September 30, 2023.

Period: the quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 7, 2023, Mineralys Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2023 and provided a corporate update.

View on SEC.gov

Browse all earnings releases →

Mineralys Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001933414-23-000085

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.